Browsing Tag
Wolfe Research
5 posts
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Tango Therapeutics (TNGX) soars on striking pancreatic cancer data, then moves to cash in
Tango Therapeutics soared 50%+ on early pancreatic cancer data, a 92% response rate for vopimetostat plus daraxonrasib, then filed a $500M offering to cash in.
Oklo (NYSE: OKLO) sits at $66 as nuclear bull case meets execution reality
Data centers need power faster than utilities can build it. Oklo has 14GW of demand and an NRC win, but almost none of the pipeline is binding.
Nebius (NBIS) strikes $643m Eigen AI acquisition to anchor inference at Token Factory
Nebius has the compute. It needed the inference moat. The $643 million Eigen AI deal is how Token Factory plans to outprice Together AI and Fireworks.
Raymond James stock soars after shocking earnings beat—analysts can’t believe it!
Raymond James Financial Inc. (NYSE: Raymond James) has experienced a notable surge in its share price following the…